Necitumumab in combination with chemotherapy can prolong survival by nearly 10 months in NSCLC patients with high EGFR expression (Thatcher et al., 2015) and has been approved as a first-line method for the treatment of advanced NSCLC (Table 1). Here, EGFR is linked to non-small cell lung carcinoma.